Review
Urology & Nephrology
Marcin Adamczak, Stanislaw Surma
Summary: Metabolic acidosis in CKD patients is common and can contribute to disease progression and various complications, worsening patient prognosis. Currently, sodium bicarbonate is the main treatment for metabolic acidosis. The role of the new drug veverimer in metabolic acidosis therapy requires further study.
Article
Medicine, General & Internal
Yunting Wang, Ling Chen, Guangfeng Guo, Youyuan Gao, Hua Gan
Summary: This study found that sodium bicarbonate (SB) infusion did not have a beneficial effect on hospital mortality in AKI patients with metabolic acidosis overall. However, it was observed to have a significant correlation with improved hospital mortality in patients with high anion gap (AG) metabolic acidosis. Larger randomized controlled trials are needed to confirm these results.
FRONTIERS IN MEDICINE
(2023)
Article
Urology & Nephrology
Antonia Zhu, Reid H. Whitlock, Thomas W. Ferguson, Mohammad Nour-Mohammadi, Paul Komenda, Claudio Rigatto, David Collister, Clara Bohm, Nancy L. Reaven, Susan E. Funk, Navdeep Tangri
Summary: Metabolic acidosis is associated with a higher risk of acute kidney injury in patients with chronic kidney disease. AKI should be considered as an outcome in studies of treatments for patients with metabolic acidosis.
KIDNEY INTERNATIONAL REPORTS
(2022)
Article
Pharmacology & Pharmacy
Sai Huang, Yaojun Peng, Lili Wang, Jing Wang, Xuan Zhou, Xiang Cui, Li Chen, Bo Yang, Cong Feng
Summary: This study aimed to explore the effectiveness of sodium bicarbonate infusion on mortality in elderly septic patients with acute metabolic acidosis. The results suggested that sodium bicarbonate infusion could improve both ICU and hospital survival for elderly septic patients with acute metabolic acidosis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Urology & Nephrology
Navdeep Tangri, Thomas W. Ferguson, Nancy L. Reaven, Julie Lai, Susan E. Funk, Vandana Mathur
Summary: Low serum bicarbonate at a single point in time is associated with accelerated kidney decline in patients with chronic kidney disease (CKD). This study modeled how changes in serum bicarbonate over time affect the incidence of adverse kidney outcomes, and the results showed that an increase in serum bicarbonate in CKD patients with metabolic acidosis is associated with a decreased risk of kidney disease progression.
KIDNEY INTERNATIONAL REPORTS
(2023)
Article
Pharmacology & Pharmacy
Huabin Wang, Rui Liang, Tianqi Liang, Songyao Chen, Yulong Zhang, Lidan Zhang, Chun Chen
Summary: Sodium bicarbonate (SB) infusion does not reduce in-hospital mortality in severely ill children with metabolic acidosis and is associated with increased risk of hypernatraemia, hypokalaemia, and hypocalcaemia. Efforts should be focused on eliminating the causes of metabolic acidosis rather than using SB excessively.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Transplantation
Vandana S. Mathur, Elizabeth Li, Donald E. Wesson
Summary: Veverimer effectively treats metabolic acidosis in patients with diabetes and CKD, significantly improving their quality of life and physical function.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Ophthalmology
Yi-chun Wang, Xiao chun Ling, Wen-hsin Tsai, Jia-sin Liu, Ko-lin Kuo
Summary: This study investigated the risks of metabolic acidosis and renal outcomes in patients with primary open-angle glaucoma and advanced chronic kidney disease (CKD) after using topical carbonic anhydrase inhibitor (CAI). The results showed that CAI users had a higher incidence of long-term dialysis and metabolic acidosis compared to non-users.
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Critical Care Medicine
Tomoko Fujii, Andrew A. Udy, Alistair Nichol, Rinaldo Bellomo, Adam M. Deane, Khaled El-Khawas, Naorungroj Thummaporn, Ary Serpa Neto, Hannah Bergin, Robert Short-Burchell, Chin-Ming Chen, Kuang-Hua Cheng, Kuo-Chen Cheng, Clemente Chia, Feng-Fan Chiang, Nai-Kuan Chou, Timothy Fazio, Pin-Kuei Fu, Victor Ge, Yoshiro Hayashi, Jennifer Holmes, Ting-Yu Hu, Shih-Feng Huang, Naoya Iguchi, Sarah L. Jones, Toshiyuki Karumai, Shinshu Katayama, Shih-Chi Ku, Chao-Lun Lai, Bor-Jen Lee, Wen-Jinn Liaw, Chelsea T. W. Ong, Lisa Paxton, Chloe Peppin, Owen Roodenburg, Shinjiro Saito, John D. Santamaria, Yahya Shehabi, Aiko Tanaka, Ravindranath Tiruvoipati, Hsiao-En Tsai, An-Yi Wang, Chen-Yu Wang, Yu-Chang Yeh, Chong-Jen Yu, Kuo-Ching Yuan
Summary: Metabolic acidosis is a major complication of critical illness. Early sodium bicarbonate therapy may improve mean arterial pressure in critically ill patients and reduce the risk of ICU mortality.
Article
Urology & Nephrology
Vandana Mathur, Nancy L. Reaven, Susan E. Funk, Reid Whitlock, Thomas W. Ferguson, David Collister, Navdeep Tangri
Summary: This study quantified the independent association between metabolic acidosis and adverse muscle, bone, and functional outcomes in a large US community-based cohort. The results showed that the presence and severity of metabolic acidosis were significant independent risk factors for failure to thrive, protein-calorie malnutrition, and fall or fracture in patients with stage 3-5 CKD.
CLINICAL KIDNEY JOURNAL
(2022)
Article
Critical Care Medicine
Ary Serpa Neto, Tomoko Fujii, Mairead Mcnamara, James Moore, Paul J. Young, Sandra Peake, Michael Bailey, Carol Hodgson, Alisa M. Higgins, Emily J. See, Paul Secombe, Lewis Campbell, Meredith Young, Mikihiro Maeda, David Pilcher, Alistair Nichol, Adam Deane, Elisa Licari, Kyle White, Craig French, Yahya Shehabi, Anthony Cross, Matthew Maiden, Umesh Kadam, Khaled El Khawas, Jamie Cooper, Rinaldo Bellomo, Andrew Udy
Summary: This study aims to identify the best population, intervention design, and assess between-group biochemical separation in preparation for a future phase III trial. The study includes 30 patients aged 18 and above who were admitted to the ICU within 48 hours, receiving vasopressor treatment, and presenting metabolic acidosis. The findings confirm the feasibility of a larger phase III trial on sodium bicarbonate.
CRITICAL CARE MEDICINE
(2023)
Article
Materials Science, Multidisciplinary
Ujjawal Bairagi, Simran Kaur Rainu, Neetu Singh, Josemon Jacob
Summary: We report on cytocompatible, charged polyzwitterionic nanogels (PZNGs) that can efficiently fix and release bicarbonate anions for the treatment of metabolic acidosis. The PZNGs show good stability and cytocompatibility, and exhibit sustained release of bicarbonate anions for up to 168 hours.
ACS APPLIED POLYMER MATERIALS
(2023)
Article
Transplantation
Vandana S. Mathur, David A. Bushinsky, Lesley Inker, Gerrit Klaerner, Elizabeth Li, Dawn Parsell, Vlado Perkovic, Yuri Stasiv, Michael Walker, Donald E. Wesson, David C. Wheeler, Navdeep Tangri
Summary: The VALOR-CKD trial aims to evaluate the impact of veverimer on the progression of kidney disease in patients with metabolic acidosis and CKD. The trial has recruited a large population of high-risk CKD patients to study the development of kidney disease and loss of kidney function. It will assess the efficacy of veverimer as a treatment option.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Medicine, General & Internal
William E. Novotny, Irma Fiordalisi, Cynthia P. Keel, Glenn D. Harris
Summary: Drinking alkaline water can induce metabolic alkalosis, which may enhance insulin sensitivity in patients with type 1 diabetes mellitus.
CLINICAL CASE REPORTS
(2021)
Review
Pharmacology & Pharmacy
Wenlin Liu, Lili Li, Xuemei Zhang, Haonan Dong, Miaomiao Lu
Summary: Veverimer is effective in increasing bicarbonate levels and improving physical function in CKD patients with metabolic acidosis, compared to placebo, with similar safety profiles. Further research is needed to compare long-term veverimer use with traditional alkali therapy.
FRONTIERS IN PHARMACOLOGY
(2021)